Top U.S. Officials Head to Congress to Defend Virus Response

Trump administration officials appeared on Capitol Hill Friday to defend the federal government’s response to the coronavirus crisis, at a hearing hosted by a House panel calling for a national plan to contain the virus.

Top leaders from theNational Institutes of Health, the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services plan to highlight public-health interventions, vaccine and therapeutic development work and the build-out of testing infrastructure, according to prepared testimony.

Officials including Robert Redfield, director of the CDC, and Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, will inventory measures taken to improve testing and develop therapeutics and vaccines, according to the testimony. But the prepared remarks don’t discuss what many health experts say is needed and the hearing is on: A national strategy to contain the coronavirus to replace the current state-by-state piecemeal effort.

Covid-19 “is the most significant public health challenge to face our nation in more than a century,” the officials said in a joint statement.

67,619 in U.S.Most new cases today

-4% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23

-1.​204 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23

4.​4% Global GDP Tracker (annualized), June

The U.S. marked another grim milestone this week, with total fatalities from Covid-19 topping 150,000. More than four million Americans have been infected. A recent surge in cases in Sun Belt states has shown signs of moderating, though deaths have continued to rise, with Florida, Arizona and Texasposting records on Thursday.

Representative James Clyburn, the Democratic chairman of the House panel, urged health officials to “prioritize science over politics,” distribute tests and provide clear guidance to Americans to stop the spread of the virus.

“It is clear that the administration’s approach of deferring to the states, sidelining the experts and rushing to reopen has prolonged this virus and led to thousands of preventable deaths,” Clyburn said. “We do not need to lose another 150,000 American lives. But if we don’t make drastic changes now, this tragic outcome is well within the realm of possibility.”

Representative Steve Scalise, the panel’s top Republican, said there is a national plan that is already working.

“Let’s not forget the things that have already been done as part of this plan that have saved millions of lives,” Scalise said, talking to health officials at the hearing. “We mourn every loss but let’s also recognize the lives that would’ve been lost if you weren’t on the job carrying out President Trump’s plan to contain this.”

Testing Plans

President Donald Trump has defended his administration’s response and says the government is making progress. He said at a White House briefing on Thursday that “we know a great deal about the virus and how to treat it and who it targets.”

On testing, the officials outlined a framework for diagnosing and mitigating disease. They acknowledged limitations in supply that have handicapped capacity in many parts of the country, but said “federal leadership has guided efforts to combat these challenges in close collaboration with states, local jurisdictions, and the private sector.”

Evidence of improving test capacity, however, is mixed. While one major laboratory said this week that turnaround times had improved, another said the average time to produce results for non-priority patients remained seven days, on average.

The hearing is likely to touch on other issues as well, including new risks posed by flu season.

“If there is Covid-19 and flu activity at the same time, this could place a tremendous burden on the health care system related to bed occupancy, laboratory testing needs, personal protective equipment and health care worker safety,” the testimony said, emphasizing the importance of getting a flu vaccine.

Vaccine Work

The testimony highlighted the NIAID’s work on vaccines, including its long collaboration withModerna Inc. that led to the start of the first U.S. final-stage trial of a candidate on Monday. NIAID scientists have also helped with a variety of other vaccines, including one being developed by theUniversity of Oxford andAstraZeneca Plc, according to the testimony.

“There is growing optimism that one or more of these vaccine candidates will prove safe and effective by late 2020 or early 2021,” according to the testimony.

NIAID also plans to start a series of human studies to test antibodies against the virus. At least 21 companies are developing monoclonal antibodies against the disease, according to the testimony.

The officials also plan to speak about data issues that have plagued the country’s response for months, according to the prepared remarks. States included more race and ethnicity data in their reports by late July, as compared with April, the officials said. The development comes in advance of a new HHS requirement for laboratories to submit these and other details by the start of August.

“This crisis has highlighted the need to continue efforts to modernize the public health data systems that CDC and states rely on for accurate data,” the prepared remarks said. “Timely and accurate data are essential as CDC and the nation work to understand the impact of Covid-19 on all Americans.”

— With assistance by Olivia Raimonde, and Jeannie Baumann

Source: Read Full Article